ID   LPRG_MYCTU              Reviewed;         236 AA.
AC   P9WK45; L0T868; O32852; P0A5I8; P71679;
DT   16-APR-2014, integrated into UniProtKB/Swiss-Prot.
DT   16-APR-2014, sequence version 1.
DT   07-APR-2021, entry version 44.
DE   RecName: Full=Lipoarabinomannan carrier protein LprG {ECO:0000305|PubMed:25232742, ECO:0000305|PubMed:25356793};
DE   AltName: Full=27 kDa lipoprotein;
DE   AltName: Full=Antigen P27 {ECO:0000303|PubMed:14998516};
DE   AltName: Full=Lipoprotein LprG;
DE   AltName: Full=Triacylated glycolipid carrier LprG {ECO:0000303|PubMed:20694006};
DE   AltName: Full=Triacylglyceride transfer protein LprG {ECO:0000303|PubMed:26751071};
DE   Flags: Precursor;
GN   Name=lprG; Synonyms=lpp-27; OrderedLocusNames=Rv1411c;
GN   ORFNames=MTCY21B4.28c;
OS   Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv).
OC   Bacteria; Actinobacteria; Corynebacteriales; Mycobacteriaceae;
OC   Mycobacterium; Mycobacterium tuberculosis complex.
OX   NCBI_TaxID=83332;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 25618 / H37Rv;
RX   PubMed=9634230; DOI=10.1038/31159;
RA   Cole S.T., Brosch R., Parkhill J., Garnier T., Churcher C.M., Harris D.E.,
RA   Gordon S.V., Eiglmeier K., Gas S., Barry C.E. III, Tekaia F., Badcock K.,
RA   Basham D., Brown D., Chillingworth T., Connor R., Davies R.M., Devlin K.,
RA   Feltwell T., Gentles S., Hamlin N., Holroyd S., Hornsby T., Jagels K.,
RA   Krogh A., McLean J., Moule S., Murphy L.D., Oliver S., Osborne J.,
RA   Quail M.A., Rajandream M.A., Rogers J., Rutter S., Seeger K., Skelton S.,
RA   Squares S., Squares R., Sulston J.E., Taylor K., Whitehead S.,
RA   Barrell B.G.;
RT   "Deciphering the biology of Mycobacterium tuberculosis from the complete
RT   genome sequence.";
RL   Nature 393:537-544(1998).
RN   [2]
RP   DISRUPTION PHENOTYPE, AND VIRULENCE.
RC   STRAIN=H37Rv;
RX   PubMed=14998516; DOI=10.1016/j.micinf.2003.10.010;
RA   Bigi F., Gioffre A., Klepp L., Santangelo M.P., Alito A., Caimi K.,
RA   Meikle V., Zumarraga M., Taboga O., Romano M.I., Cataldi A.;
RT   "The knockout of the lprG-Rv1410 operon produces strong attenuation of
RT   Mycobacterium tuberculosis.";
RL   Microbes Infect. 6:182-187(2004).
RN   [3]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND FUNCTION.
RC   STRAIN=ATCC 25618 / H37Rv;
RX   PubMed=15294983; DOI=10.4049/jimmunol.173.4.2660;
RA   Gehring A.J., Dobos K.M., Belisle J.T., Harding C.V., Boom W.H.;
RT   "Mycobacterium tuberculosis LprG (Rv1411c): a novel TLR-2 ligand that
RT   inhibits human macrophage class II MHC antigen processing.";
RL   J. Immunol. 173:2660-2668(2004).
RN   [4]
RP   FUNCTION.
RC   STRAIN=H37Rv;
RX   PubMed=18156250; DOI=10.1128/jb.01046-07;
RA   Farrow M.F., Rubin E.J.;
RT   "Function of a mycobacterial major facilitator superfamily pump requires a
RT   membrane-associated lipoprotein.";
RL   J. Bacteriol. 190:1783-1791(2008).
RN   [5]
RP   FUNCTION IN INFECTION, AND GLYCOSYLATION.
RX   PubMed=18424702; DOI=10.4049/jimmunol.180.9.5833;
RA   Sieling P.A., Hill P.J., Dobos K.M., Brookman K., Kuhlman A.M., Fabri M.,
RA   Krutzik S.R., Rea T.H., Heaslip D.G., Belisle J.T., Modlin R.L.;
RT   "Conserved mycobacterial lipoglycoproteins activate TLR2 but also require
RT   glycosylation for MHC class II-restricted T cell activation.";
RL   J. Immunol. 180:5833-5842(2008).
RN   [6]
RP   FUNCTION IN INFECTION.
RC   STRAIN=H37Rv;
RX   PubMed=19362712; DOI=10.1016/j.cellimm.2009.03.008;
RA   Drage M.G., Pecora N.D., Hise A.G., Febbraio M., Silverstein R.L.,
RA   Golenbock D.T., Boom W.H., Harding C.V.;
RT   "TLR2 and its co-receptors determine responses of macrophages and dendritic
RT   cells to lipoproteins of Mycobacterium tuberculosis.";
RL   Cell. Immunol. 258:29-37(2009).
RN   [7]
RP   FUNCTION, AND GLYCOSYLATION.
RC   STRAIN=ATCC 25177 / H37Ra, and H37Rv;
RX   PubMed=21078852; DOI=10.1128/iai.00806-10;
RA   Lancioni C.L., Li Q., Thomas J.J., Ding X., Thiel B., Drage M.G.,
RA   Pecora N.D., Ziady A.G., Shank S., Harding C.V., Boom W.H., Rojas R.E.;
RT   "Mycobacterium tuberculosis lipoproteins directly regulate human memory
RT   CD4(+) T cell activation via Toll-like receptors 1 and 2.";
RL   Infect. Immun. 79:663-673(2011).
RN   [8]
RP   SUBCELLULAR LOCATION.
RC   STRAIN=H37Rv;
RX   PubMed=21364279; DOI=10.1172/jci44261;
RA   Prados-Rosales R., Baena A., Martinez L.R., Luque-Garcia J., Kalscheuer R.,
RA   Veeraraghavan U., Camara C., Nosanchuk J.D., Besra G.S., Chen B.,
RA   Jimenez J., Glatman-Freedman A., Jacobs W.R. Jr., Porcelli S.A.,
RA   Casadevall A.;
RT   "Mycobacteria release active membrane vesicles that modulate immune
RT   responses in a TLR2-dependent manner in mice.";
RL   J. Clin. Invest. 121:1471-1483(2011).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, AND DISRUPTION PHENOTYPE.
RC   STRAIN=H37Rv;
RX   PubMed=21762531; DOI=10.1186/1471-2334-11-195;
RA   Bianco M.V., Blanco F.C., Imperiale B., Forrellad M.A., Rocha R.V.,
RA   Klepp L.I., Cataldi A.A., Morcillo N., Bigi F.;
RT   "Role of P27 -P55 operon from Mycobacterium tuberculosis in the resistance
RT   to toxic compounds.";
RL   BMC Infect. Dis. 11:195-195(2011).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   STRAIN=ATCC 25618 / H37Rv;
RX   PubMed=21969609; DOI=10.1074/mcp.m111.011627;
RA   Kelkar D.S., Kumar D., Kumar P., Balakrishnan L., Muthusamy B., Yadav A.K.,
RA   Shrivastava P., Marimuthu A., Anand S., Sundaram H., Kingsbury R.,
RA   Harsha H.C., Nair B., Prasad T.S., Chauhan D.S., Katoch K., Katoch V.M.,
RA   Kumar P., Chaerkady R., Ramachandran S., Dash D., Pandey A.;
RT   "Proteogenomic analysis of Mycobacterium tuberculosis by high resolution
RT   mass spectrometry.";
RL   Mol. Cell. Proteomics 10:M111.011627-M111.011627(2011).
RN   [11]
RP   SUBCELLULAR LOCATION, AND DOMAIN.
RX   PubMed=25041568; DOI=10.1111/cbdd.12365;
RA   Ocampo M., Curtidor H., Vanegas M., Patarroyo M.A., Patarroyo M.E.;
RT   "Specific interaction between Mycobacterium tuberculosis lipoprotein-
RT   derived peptides and target cells inhibits mycobacterial entry in vitro.";
RL   Chem. Biol. Drug Des. 84:626-641(2014).
RN   [12]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RC   STRAIN=H37Rv;
RX   PubMed=25232742; DOI=10.1371/journal.ppat.1004376;
RA   Gaur R.L., Ren K., Blumenthal A., Bhamidi S., Gibbs S., Jackson M.,
RA   Zare R.N., Ehrt S., Ernst J.D., Banaei N.;
RT   "LprG-mediated surface expression of lipoarabinomannan is essential for
RT   virulence of Mycobacterium tuberculosis.";
RL   PLoS Pathog. 10:E1004376-E1004376(2014).
RN   [13]
RP   ERRATUM OF PUBMED:25232742.
RX   PubMed=26650245; DOI=10.1371/journal.ppat.1005336;
RA   Gaur R.L., Ren K., Blumenthal A., Bhamidi S., Gibbs S., Jackson M.,
RA   Zare R.N., Ehrt S., Ernst J.D., Banaei N.;
RT   "Correction: LprG-mediated surface expression of lipoarabinomannan is
RT   essential for virulence of Mycobacterium tuberculosis.";
RL   PLoS Pathog. 11:E1005336-E1005336(2015).
RN   [14]
RP   FUNCTION, LIPID-BINDING, DISRUPTION PHENOTYPE, AND MUTAGENESIS OF VAL-91.
RC   STRAIN=H37Rv;
RX   PubMed=25356793; DOI=10.1371/journal.ppat.1004471;
RA   Shukla S., Richardson E.T., Athman J.J., Shi L., Wearsch P.A., McDonald D.,
RA   Banaei N., Boom W.H., Jackson M., Harding C.V.;
RT   "Mycobacterium tuberculosis lipoprotein LprG binds lipoarabinomannan and
RT   determines its cell envelope localization to control phagolysosomal
RT   fusion.";
RL   PLoS Pathog. 10:E1004471-E1004471(2014).
RN   [15]
RP   REVIEW.
RX   PubMed=20234378; DOI=10.1038/nrmicro2321;
RA   Harding C.V., Boom W.H.;
RT   "Regulation of antigen presentation by Mycobacterium tuberculosis: a role
RT   for Toll-like receptors.";
RL   Nat. Rev. Microbiol. 8:296-307(2010).
RN   [16] {ECO:0007744|PDB:3MH8, ECO:0007744|PDB:3MH9, ECO:0007744|PDB:3MHA}
RP   X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 28-236, FUNCTION, DOMAIN,
RP   LIPID-BINDING, PALMITOYLATION AT CYS-27, DIACYLGLYCEROL AT CYS-27, AND
RP   MUTAGENESIS OF VAL-91.
RC   STRAIN=H37Rv;
RX   PubMed=20694006; DOI=10.1038/nsmb.1869;
RA   Drage M.G., Tsai H.C., Pecora N.D., Cheng T.Y., Arida A.R., Shukla S.,
RA   Rojas R.E., Seshadri C., Moody D.B., Boom W.H., Sacchettini J.C.,
RA   Harding C.V.;
RT   "Mycobacterium tuberculosis lipoprotein LprG (Rv1411c) binds triacylated
RT   glycolipid agonists of Toll-like receptor 2.";
RL   Nat. Struct. Mol. Biol. 17:1088-1095(2010).
RN   [17] {ECO:0007744|PDB:4ZRA}
RP   X-RAY CRYSTALLOGRAPHY (1.83 ANGSTROMS) OF 36-231 IN COMPLEX WITH
RP   TRIACYLGLYCERIDE, FUNCTION, DOMAIN, TRIACYLGLYCERIDE-BINDING, DISRUPTION
RP   PHENOTYPE, AND MUTAGENESIS OF VAL-91.
RC   STRAIN=H37Rv;
RX   PubMed=26751071; DOI=10.1371/journal.ppat.1005351;
RA   Martinot A.J., Farrow M., Bai L., Layre E., Cheng T.Y., Tsai J.H.,
RA   Iqbal J., Annand J.W., Sullivan Z.A., Hussain M.M., Sacchettini J.,
RA   Moody D.B., Seeliger J.C., Rubin E.J.;
RT   "Mycobacterial metabolic syndrome: LprG and Rv1410 regulate
RT   triacylglyceride levels, growth rate and virulence in Mycobacterium
RT   tuberculosis.";
RL   PLoS Pathog. 12:E1005351-E1005351(2016).
CC   -!- FUNCTION: Probably helps membrane protein Rv1410c (P55) transport
CC       triacylglycerides (TAG) across the inner cell membrane into the
CC       periplasm; TAG probably regulates lipid metabolism and growth
CC       regulation (PubMed:26751071). Binds TAG and transfers it between lipid
CC       bilayers, probably to the outer membrane in vivo (PubMed:26751071).
CC       Binds di- and triacylated phosphatidyl-myo-inositol mannosides (PIMs),
CC       and glycolipid lipoglycan modulins lipoarabinomannan (LAM) and
CC       lipomannan (LM), facilitating their recognition by TLR2
CC       (PubMed:20694006, PubMed:25356793). Binds LM > PIM6 > ManLAM > PI-LAM >
CC       PIM2 (mannose-capped LAM and phospho-myo-inositol-capped LAM, E.coli
CC       expressed without acyl-groups); deacylated LM and LAM also bind to this
CC       protein via their mannose moieties, showing LprG has at least 2
CC       different ways to bind glycolipids (PubMed:25356793). Binds
CC       triacylglycerides (TAG) in the same cavity, is able to transfer TAG
CC       between lipid bilayers (PubMed:26751071). Overexpression of LprG and
CC       Rv1410c leads to increased levels of TAG in the culture medium
CC       (PubMed:26751071). Required for Rv1410c-mediated export of drugs
CC       (PubMed:18156250, PubMed:21762531). Required, probably with Rv1410c,
CC       for normal surface localization of LAM (PubMed:25232742).
CC       {ECO:0000269|PubMed:18156250, ECO:0000269|PubMed:20694006,
CC       ECO:0000269|PubMed:21762531, ECO:0000269|PubMed:25232742,
CC       ECO:0000269|PubMed:25356793, ECO:0000269|PubMed:26751071}.
CC   -!- FUNCTION: A host TLR2 agonist (toll-like receptor), shown
CC       experimentally for human and mouse (PubMed:19362712). Inhibits primary
CC       human macrophage MHC-II Ag processing via TLR2 (PubMed:15294983). Both
CC       lipidated and nonlipidated protein act as TLR2 agonists in antigen-
CC       presenting cells, although lipidated protein is more efficient
CC       (PubMed:20694006). In resting human CD4+ T-cells lipidated but not
CC       nonlipidated protein is a costimulatory ligand (with anti-CD3 and anti-
CC       CD28) for T-cell proliferation and IFN-gamma and IL-2 production,
CC       leading to increased expression of early T-cell activation markers,
CC       TLR2 and NFKB3 phosphorylation (PubMed:21078852). Human CD4+ T-cells
CC       use TLR1/TLR2 heterodimers to respond to this and probably other
CC       mycobacterial lipoproteins (PubMed:21078852). Able to stimulate
CC       proliferation of CD4+ T-cells derived from a human leprosy patient
CC       following protein processing/presentation by MHC class II molecules in
CC       peripheral blood mononuclear cells (PubMed:18424702). Requires both
CC       host TLR1 and TLR2 as coreceptors to elicit host response in mouse,
CC       although TLR6 may play a redundant role, has a partial requirement for
CC       CD14 as an accessory receptor (PubMed:19362712).
CC       {ECO:0000269|PubMed:15294983, ECO:0000269|PubMed:18424702,
CC       ECO:0000269|PubMed:19362712, ECO:0000269|PubMed:20694006,
CC       ECO:0000269|PubMed:21078852}.
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane {ECO:0000255|PROSITE-
CC       ProRule:PRU00303, ECO:0000269|PubMed:21762531, ECO:0000305}; Lipid-
CC       anchor {ECO:0000255|PROSITE-ProRule:PRU00303}. Secreted, cell wall
CC       {ECO:0000269|PubMed:21762531}. Secreted {ECO:0000269|PubMed:21762531}.
CC       Cell surface {ECO:0000269|PubMed:25041568}. Note=Present in
CC       extracytoplasmic vesicles (PubMed:21364279). Immunoelectron microscopy
CC       indicates this protein is close to the cell surface (PubMed:25041568).
CC       {ECO:0000269|PubMed:21364279, ECO:0000269|PubMed:25041568}.
CC   -!- DOMAIN: Forms a U-shaped beta-half-barrel with a small hydrophobic
CC       cavity (1500 Angstroms (3)) which holds a triacylated PIM in 1 crystal
CC       structure; the 3 acyl chains are within the cavity while the sugar
CC       moieties bind to the protein surface (PubMed:20694006). In the
CC       structure bound to triacylglycerides (TAG) 2 of the 3 acyl chains are
CC       buried in the cavity, the third is solvent exposed (PubMed:26751071). A
CC       flexible lid region may move to accommodate different TAG molecules
CC       (PubMed:26751071). Fragments of the mature protein (residues 81-100,
CC       141-160 and 218-236) prevent uptake of M.tuberculosis by a human
CC       macrophage-like cell line; lesser effects are seen on bacterial uptake
CC       by a human lung epithelial cell line (PubMed:25041568).
CC       {ECO:0000269|PubMed:20694006, ECO:0000269|PubMed:25041568,
CC       ECO:0000269|PubMed:26751071}.
CC   -!- PTM: Modified by Lgt on Cys-27 with an S-linked diacylglyceral, signal
CC       peptide is removed by LspA, Cys-27 is further modifed with a fatty acid
CC       on its amino group by Lnt yielding a triacylated protein (Probable).
CC       Probably glycosylated, which is required for T-cell activation
CC       (PubMed:18424702). {ECO:0000250|UniProtKB:P9WK47,
CC       ECO:0000269|PubMed:18424702, ECO:0000305|PubMed:20694006}.
CC   -!- DISRUPTION PHENOTYPE: A single deletion mutant leads to loss of
CC       expression of efflux pump Rv1410c due to polar effects; in infected
CC       BALB/c mice 1.5 and 2.5 log decrease in bacterial load 15 and 35 days
CC       after infection (PubMed:14998516). The single mutant increases
CC       sensitivity to malachite green, sodium dodecyl sulfate (SDS),
CC       isoniazid, ethambutal and ethidium bromide, alters the permeability of
CC       the cell wall; both genes of the operon are required to fully restore
CC       the phenotypes (PubMed:21762531). Single deletion mutant (probably
CC       without Rv1410c) has decreased surface-exposed glycolipid
CC       lipoarabinomannan (LAM), although cellular LAM, LM and PIM content is
CC       normal (PubMed:25232742, PubMed:25356793). Disruption of either Rv1410c
CC       or the lrpG-Rv1410c operon leads to increased levels of many
CC       triacylglyceride (TAG) alkylforms; up to 100-fold increase depending on
CC       the exact TAG form (PubMed:26751071). It also forms smaller colonies on
CC       agar (PubMed:25232742). Loss of surface LAM has several consequences;
CC       bacteria enter mouse macrophages with reduced efficiency and block
CC       mouse macrophage phagosome-lysosome fusion less efficiently than wild-
CC       type (PubMed:25232742). Reduced efficiency of mouse macrophage
CC       phagosome-lysosome fusion was seen in another study (PubMed:25356793).
CC       C57BL/6 mice infected with mutant bacteria have 10-fold less bacterial
CC       burden after 10 days and about 2700-fold less burden after 70 days;
CC       attenuation of mutant is not rescued in macrophages impaired for
CC       reactive oxygen or nitrogen generation (disruption of Ncf1 or iNOS)
CC       (PubMed:25232742). {ECO:0000269|PubMed:14998516,
CC       ECO:0000269|PubMed:21762531, ECO:0000269|PubMed:25232742,
CC       ECO:0000269|PubMed:25356793, ECO:0000269|PubMed:26751071}.
CC   -!- MISCELLANEOUS: Bacterial LAM blocks host cell phagosome-lysosome fusion
CC       and is one way in which M.tuberculosis evades the host immune system.
CC       {ECO:0000305|PubMed:25232742, ECO:0000305|PubMed:25356793}.
CC   -!- MISCELLANEOUS: Triacylglycerides accumulate in lipid droplets in the
CC       cytoplasm of M.tuberculosis stationary phase and dormant bacteria, and
CC       are used as an energy source during starvation (PubMed:26751071).
CC       {ECO:0000305|PubMed:26751071}.
CC   -!- SIMILARITY: Belongs to the LppX/LprAFG lipoprotein family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL123456; CCP44170.1; -; Genomic_DNA.
DR   PIR; H70901; H70901.
DR   RefSeq; NP_215927.1; NC_000962.3.
DR   RefSeq; WP_003407315.1; NZ_NVQJ01000038.1.
DR   PDB; 3MH8; X-ray; 2.00 A; A/B=36-231.
DR   PDB; 3MH9; X-ray; 1.79 A; A/C=28-236.
DR   PDB; 3MHA; X-ray; 1.85 A; A/B=36-231.
DR   PDB; 4ZRA; X-ray; 1.83 A; A/C=36-231.
DR   PDBsum; 3MH8; -.
DR   PDBsum; 3MH9; -.
DR   PDBsum; 3MHA; -.
DR   PDBsum; 4ZRA; -.
DR   SMR; P9WK45; -.
DR   STRING; 83332.Rv1411c; -.
DR   PaxDb; P9WK45; -.
DR   GeneID; 886700; -.
DR   KEGG; mtu:Rv1411c; -.
DR   TubercuList; Rv1411c; -.
DR   eggNOG; ENOG50338Y0; Bacteria.
DR   OMA; TLTPNKW; -.
DR   PhylomeDB; P9WK45; -.
DR   Reactome; R-HSA-9636383; Prevention of phagosomal-lysosomal fusion.
DR   PHI-base; PHI:5579; -.
DR   Proteomes; UP000001584; Chromosome.
DR   GO; GO:0097691; C:bacterial extracellular vesicle; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IEA:UniProtKB-SubCell.
DR   GO; GO:0005618; C:cell wall; HDA:MTBBASE.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; HDA:MTBBASE.
DR   GO; GO:0051861; F:glycolipid binding; IDA:MTBBASE.
DR   GO; GO:0035091; F:phosphatidylinositol binding; IDA:UniProtKB.
DR   GO; GO:0006869; P:lipid transport; IEA:UniProtKB-KW.
DR   GO; GO:0009405; P:pathogenesis; IMP:MTBBASE.
DR   GO; GO:0046677; P:response to antibiotic; IEA:UniProtKB-KW.
DR   GO; GO:0052170; P:suppression by symbiont of host innate immune response; TAS:Reactome.
DR   CDD; cd16334; LppX-like; 1.
DR   InterPro; IPR029046; LolA/LolB/LppX.
DR   InterPro; IPR009830; LppX/LprAFG.
DR   Pfam; PF07161; LppX_LprAFG; 1.
DR   SUPFAM; SSF89392; SSF89392; 1.
DR   PROSITE; PS51257; PROKAR_LIPOPROTEIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Antibiotic resistance; Cell inner membrane; Cell membrane;
KW   Cell wall; Glycoprotein; Lipid transport; Lipid-binding; Lipoprotein;
KW   Membrane; Palmitate; Reference proteome; Secreted; Signal; Transport;
KW   Virulence.
FT   SIGNAL          1..26
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00303"
FT   CHAIN           27..236
FT                   /note="Lipoarabinomannan carrier protein LprG"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00303"
FT                   /id="PRO_0000018146"
FT   REGION          81..100
FT                   /note="Prevents bacterial uptake by a human macrophage-like
FT                   cell line"
FT                   /evidence="ECO:0000269|PubMed:25041568"
FT   REGION          141..160
FT                   /note="Prevents bacterial uptake by a human macrophage-like
FT                   cell line"
FT                   /evidence="ECO:0000269|PubMed:25041568"
FT   REGION          218..236
FT                   /note="Prevents bacterial uptake by a human macrophage-like
FT                   cell line"
FT                   /evidence="ECO:0000269|PubMed:25041568"
FT   LIPID           27
FT                   /note="N-palmitoyl cysteine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00303,
FT                   ECO:0000305|PubMed:20694006"
FT   LIPID           27
FT                   /note="S-diacylglycerol cysteine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00303,
FT                   ECO:0000305|PubMed:20694006"
FT   MUTAGEN         91
FT                   /note="V->W: Decreased TLR2 agonist activity, cannot
FT                   acquire lipid from mycobacterial extracts, cavity entrance
FT                   and size decrease. Binds PIM6, LM and ManLAM 10-100-fold
FT                   less well than wild-type, binds de-acylated LM and ManLAM
FT                   as well as wild-type. Decreased ability to transfer
FT                   triacylglyceride between lipid bilayers."
FT                   /evidence="ECO:0000269|PubMed:20694006,
FT                   ECO:0000269|PubMed:25356793, ECO:0000269|PubMed:26751071"
FT   HELIX           41..53
FT                   /evidence="ECO:0007744|PDB:3MH9"
FT   STRAND          57..66
FT                   /evidence="ECO:0007744|PDB:3MH9"
FT   STRAND          73..81
FT                   /evidence="ECO:0007744|PDB:3MH9"
FT   TURN            82..85
FT                   /evidence="ECO:0007744|PDB:3MH9"
FT   STRAND          86..95
FT                   /evidence="ECO:0007744|PDB:3MH9"
FT   STRAND          98..107
FT                   /evidence="ECO:0007744|PDB:3MH9"
FT   STRAND          110..116
FT                   /evidence="ECO:0007744|PDB:3MH9"
FT   STRAND          119..125
FT                   /evidence="ECO:0007744|PDB:3MH9"
FT   HELIX           126..128
FT                   /evidence="ECO:0007744|PDB:3MH9"
FT   HELIX           132..135
FT                   /evidence="ECO:0007744|PDB:3MH9"
FT   TURN            138..140
FT                   /evidence="ECO:0007744|PDB:3MH9"
FT   HELIX           142..147
FT                   /evidence="ECO:0007744|PDB:3MH9"
FT   STRAND          149..160
FT                   /evidence="ECO:0007744|PDB:3MH9"
FT   STRAND          163..172
FT                   /evidence="ECO:0007744|PDB:3MH9"
FT   HELIX           174..180
FT                   /evidence="ECO:0007744|PDB:3MH9"
FT   HELIX           182..184
FT                   /evidence="ECO:0007744|PDB:3MH9"
FT   STRAND          190..199
FT                   /evidence="ECO:0007744|PDB:3MH9"
FT   STRAND          204..212
FT                   /evidence="ECO:0007744|PDB:3MH9"
FT   STRAND          215..223
FT                   /evidence="ECO:0007744|PDB:3MH9"
SQ   SEQUENCE   236 AA;  24548 MW;  2591DAE6D2E2DC22 CRC64;
     MRTPRRHCRR IAVLAAVSIA ATVVAGCSSG SKPSGGPLPD AKPLVEEATA QTKALKSAHM
     VLTVNGKIPG LSLKTLSGDL TTNPTAATGN VKLTLGGSDI DADFVVFDGI LYATLTPNQW
     SDFGPAADIY DPAQVLNPDT GLANVLANFA DAKAEGRDTI NGQNTIRISG KVSAQAVNQI
     APPFNATQPV PATVWIQETG DHQLAQAQLD RGSGNSVQMT LSKWGEKVQV TKPPVS
//
